US FDA Approves Roche’s Oral Treatment for Advanced Breast Cancer
The oral pill extended progression-free survival to 10 months in the evERA trial and gives patients an all-oral option after hormone therapy.
- On Monday, the Food and Drug Administration approved Roche's Wilserdly combined with everolimus for adults with advanced ER-positive, HER2-negative breast cancer carrying an ESR1 mutation.
- The approval follows the phase 3 evERA trial, which showed the treatment delayed cancer progression for a median of 10 months versus standard therapy. ESR1 mutations often emerge after patients develop resistance to hormone-based treatments.
- In the ESR1-mutated group, the combination cut the risk of cancer progression or death by 62%. Regulators reviewed the application alongside Health Canada and Israel's Ministry of Health under Project Orbis, expediting approval by four weeks.
- Patients require an FDA-authorized FoundationOne Liquid CDx test to confirm the ESR1 mutation before starting treatment. Common side effects affecting at least 20% of patients include mouth sores, rash, and fatigue, largely from the accompanying everolimus.
- The FDA is separately reviewing giredestrant for early-stage ER-positive breast cancer, with a decision expected by November 30, though survival data from the current approval remain immature. Doctors caution patients against switching treatments without consulting their oncology team.
20 Articles
20 Articles
For certain patients with advanced breast cancer, there will soon be a new drug on the US market. The Swiss company Roche is aiming for further approval there. However, the path is not without setbacks.
The Wilserdly, administered in combination with the everolimus, targets breast cancers with mutation of the ESR1 gene. The Basel laboratory anticipates up to 500 million francs of income as of 2026The Basel giant Roche will be able to launch on the American market a new oral treatment of hormone-dependent breast cancer under the name Wilserdly (girédestrant) in association with everolimus. It could bring up to half a billion francs from next yea…
A new drug raises expectations for better treatment of breast cancer. Roche has now received US approval, but development has not gone without setbacks.
The U.S. Medicines Agency FDA allows a new drug against advanced breast cancer. It is intended to significantly improve the chances of survival.
U.S. Food and Drug Administration Approves FoundationOne®Liquid CDx as the First Companion Diagnostic in the U.S. for WILSERDLY (giredestrant) in Combination with Everolimus for ER-Positive, HER2-Negative, ESR1-Mutated Advanced Breast Cancer
BOSTON--(BUSINESS WIRE)--Nov 16, 2026-
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium



















